ASCO 2020: Researchers underscore efficacy of pembrolizumab plus

$ 16.99

4.9 (635) In stock

Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti

Patient response to pembrolizumab plus chemotherapy and placebo plus

ASCO GU 2023: Pembrolizumab plus Docetaxel for Patients with mCRPC: Randomized, Double-Blind, Phase 3 KEYNOTE-921 Study

/curroncol/curroncol-30-00280/article_

Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost- Effectiveness Analysis

Esophageal cancer: taking immunotherapy one step further - memoinOncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)

Immunotherapy: combination regimens and new data on the significance of mutations - memoinOncology

Cancers, Free Full-Text